Autologous Dendritic Cell Therapy for Type 1 Diabetes Suppression: A Safety Study

NCT00445913 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
10
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

University of Pittsburgh